CLL/SLL stands for chronic lymphocytic leukemia/small lymphocytic lymphoma. They are the same disease, involving the slow, uncontrolled growth of a type of white blood cell called a B lymphocyte. The only difference is where the abnormal cells accumulate: in CLL, they circulate in the bloodstream, while in SLL, they collect primarily in the lymph nodes and spleen. The five-year relative survival rate for CLL/SLL is approximately 89.6%, and many people live with it for years without needing treatment.
How CLL and SLL Differ
Despite having two names, CLL and SLL are biologically the same cancer. SLL is considered the “non-leukemic form” of the disorder. The distinction comes down to a blood test. If your blood contains more than 5 billion clonal B lymphocytes per liter, it’s classified as CLL. If the count is below that threshold but you have swollen lymph nodes or an enlarged spleen filled with those same abnormal cells, the diagnosis is SLL.
There’s also a precursor condition called monoclonal B-cell lymphocytosis (MBL), where the clonal B-cell count is below the CLL threshold and there are no symptoms or enlarged lymph nodes. MBL doesn’t always progress to CLL, but it’s monitored over time.
Because CLL and SLL behave the same way and respond to the same treatments, doctors often group them together as CLL/SLL. The staging, prognosis, and treatment decisions are essentially identical.
Who Gets CLL/SLL
CLL/SLL is the most common leukemia in adults in Western countries. Based on SEER data from 2019 to 2023, the rate of new cases is 4.8 per 100,000 people per year. The median age at diagnosis is 71, making it predominantly a disease of older adults. It’s roughly twice as common in men as in women.
Symptoms and When They Appear
Most people with early CLL/SLL have no symptoms at all. The disease is frequently discovered by accident, when a routine blood test reveals an unusually high white blood cell count. When symptoms do develop, they tend to emerge gradually and can include painless swelling of lymph nodes in the neck, armpits, or groin, fatigue that doesn’t improve with rest, and a feeling of fullness in the upper left abdomen from an enlarged spleen.
A specific cluster of symptoms, sometimes called “B symptoms,” carries particular significance. These include drenching night sweats, unexplained fevers, and unintentional weight loss of more than 10% of body weight over six months. The presence of B symptoms often signals that the disease is progressing and may need treatment.
How CLL/SLL Is Staged
Two staging systems are used depending on where you live. In the United States, the revised Rai system groups patients into three risk categories:
- Low risk: High lymphocyte count in the blood and bone marrow, but no other problems. Many people remain at this stage for years.
- Intermediate risk: Lymphocytosis plus enlarged lymph nodes, spleen, or liver.
- High risk: Lymphocytosis plus anemia (hemoglobin below 11 g/dL) or a low platelet count (below 100,000 per cubic millimeter), indicating the disease is crowding out healthy blood cell production in the bone marrow.
In Europe, the Binet system uses a similar logic, classifying patients into stages A, B, and C based on how many lymph node groups are enlarged and whether blood counts have dropped.
Genetic Markers That Shape Prognosis
Not all CLL/SLL behaves the same way. Certain genetic features in the cancer cells strongly influence how aggressive the disease will be and which treatments are most effective.
A deletion on chromosome 17 (called del(17p)) is one of the most important findings. It disables a key tumor-suppressing gene called TP53, which normally helps damaged cells self-destruct. Over 90% of patients with this chromosomal deletion also carry a TP53 mutation, and the combination makes the cancer resistant to many standard therapies. Roughly 40% of patients with a TP53 mutation don’t show the chromosomal deletion on standard testing, which is why doctors now test for both independently. About half of patients with this high-risk marker won’t need treatment within the first three years, but when they do, they generally face tougher odds.
Another important marker is IGHV mutation status. Patients whose cancer cells have mutated IGHV genes tend to have significantly better long-term survival than those with unmutated IGHV, even among high-risk groups. This marker doesn’t always predict how well the first treatment will work, but it’s consistently linked to how long patients live overall.
Watch and Wait
One of the hardest things for newly diagnosed patients to hear is that treatment often isn’t recommended right away. For early-stage, asymptomatic CLL/SLL, the standard approach is active surveillance, sometimes called “watch and wait.” This means regular blood tests and check-ups, typically every few months, without any medication.
This isn’t a passive approach or a sign that doctors aren’t taking the disease seriously. Multiple studies have shown that treating early-stage CLL/SLL before symptoms develop doesn’t improve survival and only exposes patients to side effects they don’t yet need. Treatment begins when specific triggers appear:
- Progressive bone marrow failure: hemoglobin dropping below 10 g/dL or platelets falling below 50,000 per liter
- Massively enlarged spleen: extending 6 cm or more below the rib cage, or causing symptoms
- Massively enlarged lymph nodes: 10 cm or larger in diameter, or growing rapidly
- Worsening B symptoms: fevers, drenching night sweats, significant weight loss
Some people remain on watch and wait for a decade or longer. Others need treatment within months of diagnosis. The genetic markers described above help predict which path is more likely.
Treatment Options
When treatment is needed, CLL/SLL therapy has shifted dramatically away from traditional chemotherapy toward targeted drugs that attack specific vulnerabilities in the cancer cells. The two most important drug classes are BTK inhibitors and BCL-2 inhibitors.
BTK inhibitors block a signaling protein that CLL cells depend on to survive and multiply. Several are now FDA-approved, including ibrutinib, acalabrutinib, and zanubrutinib. These are taken as daily pills, often continuously until the disease progresses or side effects become intolerable. A newer option, pirtobrutinib, is available for patients whose cancer has stopped responding to an earlier BTK inhibitor.
BCL-2 inhibitors work differently, targeting a protein that prevents cancer cells from undergoing their normal programmed death. Venetoclax is the primary drug in this class and is often combined with an antibody therapy. Unlike BTK inhibitors, venetoclax-based regimens are sometimes given for a fixed duration, typically one to two years, rather than indefinitely.
For patients with del(17p) or TP53 mutations, these targeted therapies are especially important because the cancer cells’ broken self-destruct machinery makes them resistant to traditional chemotherapy. Treatment selection depends on a combination of genetic testing results, a patient’s age and overall health, and whether the disease has been treated before.
Richter Transformation
In a small percentage of cases, CLL/SLL transforms into a fast-growing, aggressive lymphoma. This is called Richter transformation, and it occurs in an estimated 2 to 9% of CLL/SLL patients, most commonly converting into diffuse large B-cell lymphoma. An additional 0.4% of patients transform to Hodgkin lymphoma.
The warning signs are distinct from the usual slow progression of CLL/SLL. Lymph nodes suddenly enlarge, often dramatically and in specific areas rather than uniformly. Fevers, night sweats, and weight loss intensify rapidly. Some patients notice that one group of lymph nodes responds to treatment while another grows, or that lymph nodes in one area enlarge much faster than elsewhere. Richter transformation requires different, more intensive treatment than standard CLL/SLL, and outcomes are generally poorer, making prompt recognition critical.